DOTAREM

Peak

gadoterate meglumine

NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Mar 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

field. The magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency…

Clinical Trials (5)

NCT07348640Phase 3Not Yet Recruiting

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

Started Feb 2026
315 enrolled
Steno-occlusive Disease
NCT03730051Phase 4Completed

Dotarem vs Gadobutrol Contrast for Breast MRI

Started Mar 2021
300 enrolled
Breast Diseases
NCT04341129Phase 1Completed

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

Started Jul 2020
50 enrolled
Breast NeoplasmsBreast DiseasesBreast Fibroadenoma+1 more
NCT03937921N/ACompleted

Dotarem Evaluation for Myocardial Perfusion CMR

Started Jul 2019
90 enrolled
Myocardial Perfusion ImagingMagnetic Resonance Imaging
NCT03602339Phase 4Completed

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

Started Nov 2018
157 enrolled
Magnetic Resonance Imaging